THERAPY DOSSIER · th-f280e146df7c

1-(4-nitrobenzenesulfonyl)-4-phenylpiperazine (Compound #5)

Drug · 1-(4-nitrobenzenesulfonyl)-4-phenylpiperazine (Compound #5); synthetic small molecule, not in ChEMBL name search.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: 1-(4-nitrobenzenesulfonyl)-4-phenylpiperazine (Compound #5); synthetic small molecule, not in ChEMBL name search.
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30825974 ↗2018Reported benefit

1-(4-nitrobenzenesulfonyl)-4-penylpiperazine increases the number of Peyer's patch-associated regenerating crypts in the small intestines after radiation injury.

MouseRadiationC3Hf/Sed//Kam; C57BL/6; Lgr5-EGFP-IRES-creERT2female stated for the Lgr5-EGFP mice; not stated for C3Hf/Sed//Kamn = Total not stated; at least three animals per groupsubcutaneous injection5 mg/kg in 15 uL DMSO suspended in 1 mL of 1 percent Cremop…24 h after irradiation

Model: Total body X-ray irradiation, 0 or 12 Gy at 5.519 Gy/min, 300 kV beam

Compound #5 increased the number of visible Peyer's patches and CD45 positive cells after 12 Gy and raised the number of Peyer's patch-associated regenerating crypts about 2.6-fold versus solvent control.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…